The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, briefly discusses highlights from the ASH 2025 meeting in the field of light chain (AL) amyloidosis, noting several promising therapies expected to be transformative in the management of patients with the disease. Prof. Sanchorawala explains that many key trials are currently being conducted in patients with relapsed/refractory (R/R) AL amyloidosis, but are likely to move forward to the newly diagnosed setting soon. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are multiple clinical trials that are being presented at the 67th annual American Society of Hematology meeting in Orlando. And the most exciting in AL amyloidosis are the results of BCMA-directed therapies, BCMA CAR-T, which is NXC-201, as well as bispecific BCMA-CD3 bispecific antibodies, etentamig, Elranatamab, and some real-world data on Teclistamab. These data are extremely, extremely exciting...
There are multiple clinical trials that are being presented at the 67th annual American Society of Hematology meeting in Orlando. And the most exciting in AL amyloidosis are the results of BCMA-directed therapies, BCMA CAR-T, which is NXC-201, as well as bispecific BCMA-CD3 bispecific antibodies, etentamig, Elranatamab, and some real-world data on Teclistamab. These data are extremely, extremely exciting. They are going to be transformative in management of patients with AL amyloidosis. And these trials are currently being conducted in patients with relapsed/refractory AL amyloidosis. However, I’m sure that these agents are going to move forward in newly diagnosed setting pretty soon as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
